Thursday, October 15, 2026

Abaxx Exchange Hits Record Volume While Fending Off Viceroy Short Report

Abaxx Exchange logged its best-ever trading month in June 2026, days after short-seller Viceroy Research accused parent Abaxx Technologies of wrongdoing. Regulators in Singapore and Canada are now reviewing the dispute, a cross-border test case for how exchanges answer short-and-distort campaigns.

LM Salvado
LM Salvado

July 12, 2026

Source Trace Score2 source documents2 with a live linkVerifiability: Strong
Abaxx Exchange Hits Record Volume While Fending Off Viceroy Short Report
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Abaxx Exchange posted record trading volume in June 2026, days after short-seller Viceroy Research accused parent Abaxx Technologies of wrongdoing.1 The spike gives Abaxx a data-driven rebuttal to the allegations.

The clash spans two financial hubs. Abaxx Technologies is dual-listed in Toronto and holds exchange operations tied to Singapore, so the fallout now runs through regulators on two continents.1 Viceroy's report used a short-and-distort strategy, publishing negative claims while holding a short position.2 Abaxx has rejected the findings as misinformation.1

Short-and-distort campaigns are a recurring feature of global markets, from Hindenburg Research's assaults on firms in the US and India to activist shorts targeting Chinese and European issuers. Abaxx's response follows a familiar international playbook: hire outside counsel and push the fight into regulatory channels.1

Abaxx retained law firm Paul Weiss to investigate the allegations.1 It also engaged two regulators directly: Singapore's Monetary Authority (MAS) and Canada's Investment Regulatory Organization (CIRO).1 The CIRO request goes further than a standard rebuttal, asking the regulator to examine Viceroy's own trading around the report's release.1 That puts the short-seller's tactics, not just its claims, under cross-border scrutiny.

For traders worldwide, June's volume record is the harder data point. A short-and-distort report aims to pressure a stock price by amplifying negative claims. Record activity on Abaxx Exchange in the same window suggests participants kept transacting rather than pulling back, even as headline risk around the parent company escalated.1

The dispute now runs on two tracks. Paul Weiss's investigation and the regulatory reviews at MAS and CIRO will determine whether Viceroy's allegations hold up.1 Meanwhile, Abaxx Exchange's trading desk has already delivered its own answer: record June volumes, an outcome that runs counter to what a short-and-distort campaign typically produces.1

Sentiment remains mixed but improving, reflecting a global market weighing unresolved regulatory questions in two jurisdictions against the exchange's demonstrated trading strength.12

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score2 source documents2 with a live linkVerifiability: Strong
  1. [1]Press releaseGlobeNewswire· June 22, 2026
    Abaxx Continues to Provide Facts Refuting Ongoing Misinformation and Reaffirms Strong Business Fundamentals
  2. [2]Press releaseGlobeNewswire· June 30, 2026
    Raytech Holding Limited Announces Closing of Approximately $6.2 Million Registered Direct Offering of its Ordinary Shares

In this story · Knowledge Files

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com